Alternatives to gastric band surgery are increasingly sought as the popularity of gastric banding has declined sharply in the UK, with bypass and sleeve procedures now dominating bariatric practice. Whether you don't meet NICE surgical criteria, wish to avoid the risks of major surgery, or are exploring all available options first, there is a growing range of evidence-based alternatives. These include licensed prescription medicines such as semaglutide (Wegovy), endoscopic procedures like intragastric balloons, and structured NHS weight management programmes. This article outlines the main options available in the UK, what the evidence shows, and how to discuss the right approach with your GP.

Why Some People Look for Alternatives to Gastric Band Surgery

Gastric band surgery has declined due to higher complication rates and less consistent outcomes compared to bypass or sleeve procedures; many people also do not meet NICE BMI criteria for any bariatric surgery.

Gastric band surgery — also known as laparoscopic adjustable gastric banding — has historically been one of the surgical options available for people living with severe obesity. However, its use has declined significantly in recent years. Data from the National Bariatric Surgery Registry (NBSR), published by the British Obesity and Metabolic Surgery Society (BOMSS), show that gastric bypass and sleeve gastrectomy procedures now account for the large majority of bariatric operations performed in the UK, as they tend to produce more consistent long-term weight loss outcomes. Gastric band surgery carries its own risks, including band slippage, erosion, port-site complications, and the need for revisional surgery, which has contributed to this shift.

For some individuals, the prospect of any major surgery is a significant concern. Surgical risks such as anaesthetic complications, infection, and prolonged recovery time can make people hesitant, particularly those with complex comorbidities. Others may not meet the clinical criteria for bariatric surgery under NICE guidance — which generally requires a BMI of 40 or above, or 35 or above with a significant obesity-related condition. It is worth noting that NICE also recommends considering surgery at a BMI of 30–34.9 for adults with recent-onset type 2 diabetes, and that lower BMI thresholds (reduced by approximately 2.5 kg/m²) apply for people from some minority ethnic groups, who are at equivalent metabolic risk at a lower BMI. Those who do not meet these criteria are therefore seeking effective non-surgical routes.

There is also growing recognition that obesity is a chronic, multifactorial condition requiring long-term management rather than a single intervention. This shift in understanding has driven the development of a broader range of treatment options, from licensed weight-loss medicines to endoscopic procedures and structured lifestyle programmes. Understanding what is available — and what is appropriate for your individual circumstances — is an important first step.

Non-Surgical Weight Loss Options Available on the NHS

The NHS offers tiered lifestyle programmes, specialist Tier 3 clinics, and some prescription medicines, though availability varies by Integrated Care Board and GP referral is usually required.

The NHS offers a range of non-surgical weight management pathways, though availability can vary considerably depending on your local Integrated Care Board (ICB). The foundation of NHS weight management support is structured lifestyle intervention, delivered through tiered services ranging from community-based programmes (Tier 2) to specialist multidisciplinary clinics (Tier 3). These services are typically accessed via GP referral.

For eligible patients, the NHS also provides access to prescription weight-loss medicines through specialist services. Some ICBs are in the process of expanding access to newer pharmacological treatments, though this is not uniform across England, and local commissioning decisions vary. If you are unsure what is available in your area, your GP or local ICB website is the best source of up-to-date information. The NHS Digital Weight Management Programme has also expanded access to structured support for people with obesity and a related condition such as type 2 diabetes or hypertension.

It is worth noting that not all options are universally available on the NHS, and some individuals choose to access certain treatments privately. If you are considering this route, it remains important to involve your GP, who can ensure that any treatment is appropriate given your full medical history, monitor for side effects, and coordinate care. Self-prescribing or purchasing weight-loss treatments without medical supervision carries significant safety risks and is strongly discouraged.

Prescription Medicines for Weight Management in the UK

Licensed UK options include orlistat, naltrexone/bupropion (Mysimba), liraglutide (Saxenda), and semaglutide (Wegovy), each requiring a qualified prescriber and use alongside dietary and lifestyle changes.

Several prescription medicines are licensed in the UK for weight management. It is important to distinguish between a medicine holding a marketing authorisation (licence) and whether it is routinely funded on the NHS — these are not always the same, and NHS commissioning criteria may be more restrictive than the licensed indications. The main options currently include:

• Orlistat (Xenical / Alli): A lipase inhibitor that reduces dietary fat absorption by approximately 30%. It is available on NHS prescription and, at a lower dose (60 mg), over the counter as Alli. Common side effects include oily stools, flatulence, and faecal urgency, particularly if a high-fat diet is consumed. It is licensed for adults with a BMI ≥30, or ≥28 with weight-related risk factors. Response should be reviewed at 12 weeks; treatment is generally continued only if at least 5% of initial body weight has been lost.

• Naltrexone/bupropion (Mysimba): A combination of an opioid receptor antagonist (naltrexone) and a noradrenergic/dopaminergic reuptake inhibitor (bupropion), which act on appetite-regulating pathways in the brain. It is licensed for adults with a BMI ≥30, or ≥27 with at least one weight-related comorbidity. Important cautions include uncontrolled hypertension, a history of seizures, and concurrent use of opioid medicines. Treatment should be discontinued if less than 5% of initial body weight has been lost after 16 weeks at the full maintenance dose. NHS availability is limited and it is more commonly accessed privately.

• Liraglutide (Saxenda): A GLP-1 receptor agonist administered as a daily subcutaneous injection. It works by mimicking the hormone GLP-1, which regulates appetite and slows gastric emptying, leading to reduced calorie intake. It is licensed for adults with a BMI ≥30, or ≥27 with a weight-related comorbidity. Treatment at the full maintenance dose (3 mg daily) should be reviewed at 12 weeks; if less than 5% of initial body weight has been lost, treatment is unlikely to be effective and should be discontinued. NHS availability for adults is limited in many areas, and it is often accessed privately.

• Semaglutide (Wegovy): A GLP-1 receptor agonist administered as a weekly subcutaneous injection. Clinical trials have demonstrated average weight loss of around 15% of body weight. Wegovy holds MHRA marketing authorisation and has been recommended by NICE (Technology Appraisal TA875) for use within specialist weight management services for adults with a BMI ≥35 alongside at least one weight-related comorbidity. Lower BMI thresholds apply for people from some minority ethnic groups. NICE TA875 specifies a maximum treatment duration of two years under NHS commissioning. Stopping criteria are set out in the Summary of Product Characteristics (SmPC) and NICE guidance.

All prescription weight-loss medicines should be used alongside dietary and lifestyle changes and are not suitable for everyone — contraindications and interactions must be assessed by a qualified prescriber. If you experience any suspected side effects from a weight-loss medicine, you can report these directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Endoscopic and Minimally Invasive Procedures to Consider

Intragastric balloons and endoscopic sleeve gastroplasty are available privately in the UK but are not routinely NHS-funded; NICE IPG guidance requires special governance and consent arrangements.

For individuals who wish to avoid major surgery but require more than pharmacological support, several endoscopic and minimally invasive procedures are available. These are not routinely commissioned by the NHS and are most commonly offered in private settings or, in some cases, as part of research programmes. NICE has published Interventional Procedures Guidance (IPG) for several of these procedures, generally recommending that they are used only with special arrangements for clinical governance, informed consent, and audit or research.

Intragastric balloon: A deflated silicone balloon is inserted into the stomach via endoscopy and then inflated with saline, reducing the stomach's capacity and promoting earlier satiety. It is typically left in place for six months before endoscopic removal. Weight loss outcomes are modest compared to bariatric surgery — averaging 10–15% of total body weight. Side effects include nausea, vomiting, and abdominal discomfort, particularly in the first few days. Rarer but more serious complications include balloon deflation or migration, gastric ulceration, and, in rare cases, bowel obstruction. NICE IPG guidance on intragastric balloon procedures should be reviewed by clinicians offering this treatment.

Endoscopic sleeve gastroplasty (ESG): This procedure uses an endoscopic suturing device to reduce the stomach's volume by approximately 70–80%, mimicking the effect of a surgical sleeve gastrectomy without external incisions. Early evidence suggests meaningful weight loss outcomes, though long-term data are still emerging. NICE has published IPG guidance on ESG, noting that current evidence on safety and efficacy is adequate to support use only with special arrangements for governance, consent, and data collection. It is not routinely commissioned on the NHS.

Aspiration therapy: A less commonly used option involving a device that allows partial drainage of stomach contents after meals. NICE IPG guidance on aspiration therapy notes that the evidence base is limited and that it should only be used with special arrangements. It is not widely offered in the UK.

If you are considering any of these procedures, it is essential to seek treatment from a provider registered with the Care Quality Commission (CQC) and to ensure that the clinician performing the procedure holds appropriate accreditation. Discussing any planned procedure with your GP beforehand is strongly advised. Any suspected complications or side effects should be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Lifestyle Interventions and Tier 3 Weight Management Services

Structured lifestyle intervention — including dietary modification, physical activity, and behavioural support — is the cornerstone of obesity management and a prerequisite for most other treatments.

Structured lifestyle intervention remains the cornerstone of weight management and is a prerequisite for most other treatments, including surgery. NICE obesity guidance (CG189 and associated public health guidance, including PH53 on lifestyle weight management services for adults) emphasises that behavioural, dietary, and physical activity support should be offered to all individuals with overweight or obesity, tailored to their individual needs and circumstances.

Tier 3 weight management services are specialist, multidisciplinary programmes typically delivered in secondary care. They involve input from dietitians, psychologists, specialist nurses, and physicians, and are designed for people with complex obesity who may be considering bariatric surgery or who have not responded to lower-intensity interventions. Referral is via your GP, and waiting times can vary significantly by region.

Key components of effective lifestyle intervention include:

• Dietary modification: Evidence supports a range of dietary approaches, including low-calorie diets, low-carbohydrate diets, and total diet replacement (TDR) programmes (such as 800 kcal/day very low-calorie diets). TDR programmes have strong evidence for type 2 diabetes remission and are offered through the NHS England Low Calorie Diet Programme for eligible adults with type 2 diabetes; clinical supervision is required and eligibility criteria apply.

• Physical activity: UK Chief Medical Officers' guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week, alongside muscle-strengthening activities on at least two days per week. Any increase in physical activity above current levels is beneficial.

• Behavioural support: Cognitive behavioural therapy (CBT)-based approaches, motivational interviewing, and group support have all demonstrated benefit in sustaining weight loss.

Digital weight management programmes, such as those commissioned by NHS England, have also expanded access to structured support, particularly for those on waiting lists or in areas with limited specialist services.

Choosing the Right Option: What to Discuss With Your GP

Your GP is the best starting point for exploring alternatives to gastric band surgery, as they can assess NHS eligibility, review your medicines, make specialist referrals, and flag safety concerns.

Navigating the range of alternatives to gastric band surgery can feel overwhelming, and the right option will depend on a number of individual factors, including your BMI, existing health conditions, previous weight loss attempts, and personal preferences. Your GP is the most appropriate starting point for this conversation and can help assess your eligibility for NHS-funded treatments, make referrals to specialist services, and ensure that any treatment you are considering is safe given your medical history.

When speaking to your GP, it may be helpful to discuss:

• Your weight history: How long you have been living with obesity, what interventions you have tried previously, and what your weight loss goals are.

• Comorbidities: Conditions such as type 2 diabetes, hypertension, sleep apnoea, or joint problems may influence which treatments are most appropriate and may affect eligibility for certain NHS-funded options.

• Medicines you are currently taking: Some weight-loss treatments interact with other medications — for example, naltrexone/bupropion is not suitable for people taking opioid medicines — and your GP will need a full medicines review before prescribing.

• Mental health: Psychological wellbeing is an important consideration in weight management. Conditions such as binge eating disorder or depression may need to be addressed alongside physical treatment.

If you are considering a privately available procedure or medicine, inform your GP so that they can flag any safety concerns and ensure continuity of care.

When to seek urgent medical advice: Contact your GP or call NHS 111 promptly if you experience persistent severe abdominal pain (which may indicate pancreatitis or gallstones, both of which are associated with GLP-1 receptor agonist treatment), persistent vomiting, or jaundice. Call 999 immediately if you develop signs of a severe allergic reaction (anaphylaxis), such as swelling of the face, lips, or throat, difficulty breathing, or collapse.

Not sure if this is normal? Chat with one of our pharmacists →

If you suspect that a weight-loss medicine or procedure has caused a side effect, you can report this to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. With the right support and a personalised approach, effective and sustainable weight management is achievable without surgery for many people.

Frequently Asked Questions